This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pratt, J. H. Articles by Ambrosius, W. T. Search for Related Content PubMed PubMed Citation Articles by Pratt, J. H. Articles by Ambrosius, W. T. Related Collections Other hypertension Clinical Studies

(Hypertension. 2001;38:1124.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Blood Pressure Responses to Small Doses of Amiloride and Spironolactone in Normotensive Subjects

J. Howard Pratt; George J. Eckert; Shirley Newman; Walter T. Ambrosius

From the Department of Medicine, Indiana University School of Medicine (J.H.P., G.J.E., S.N., W.T.A.) and the VA Medical Center (J.H.P., S.N.), Indianapolis, Ind.

Correspondence to J. Howard Pratt, MD, 541 Clinical Dr, Indianapolis, IN 46202-5111. E-mail johpratt{at}iupui.edu

Abstract—— The epithelial sodium channel (ENaC) is a principal site for sodium reabsorption and as such may participate importantly in blood pressure (BP) regulation. Amiloride, a direct inhibitor of ENaC, characteristically has mild antihypertensive properties, consistent with ENaC having more minor influences on BP regulation. Counter-regulatory influences may, however, prevent amiloride from effectively lowering BP. Aldosterone secretion is known to increase in response to the reduced sodium reabsorption that follows amiloride inhibition of ENaC, and because aldosterone upregulates ENaC function, we considered the possibility that secondary hyperaldosteronism mitigates the ability of amiloride to reduce BP. In the present study, the BP responses to amiloride (5 mg per day), spironolactone (25 mg per day), the combination of the 2 drugs, and placebo were studied in healthy normotensive subjects. Over 4 weeks of treatment, the combination of amiloride and spironolactone lowered systolic BP by 4.6±1.6 (mean±SEM) mm Hg (P=0.022) and diastolic BP by 2.2±1.2 mm Hg (P=0.30), whereas either drug alone had no significant effect on BP. The findings suggest that the 2 drugs with different modes of action—amiloride, a direct inhibitor of ENaC, and spironolactone, a mineralocorticoid receptor antagonist—may compliment each other’s ability to inhibit ENaC and thereby reduce sodium reabsorption to a point at which BP decreases. On the other hand, we cannot rule out that the BP response resulted from the greater dose of total drug. The lowering of BP with small doses of inhibitors of ENaC serves as additional evidence for the importance of ENaC to the tonic maintenance of BP.

Key Words: blood pressure • sodium channel • amiloride • spironolactone

This article has been cited by other articles:

				S. J. Hood, K. P. Taylor, M. J. Ashby, and M. J. Brown The Spironolactone, Amiloride, Losartan, and Thiazide (SALT) Double-Blind Crossover Trial in Patients With Low-Renin Hypertension and Elevated Aldosterone-Renin Ratio Circulation, July 17, 2007; 116(3): 268 - 275. [Abstract] [Full Text] [PDF]

				C. Saha, G. J. Eckert, W. T. Ambrosius, T.-Y. Chun, M. A. Wagner, Q. Zhao, and J. H. Pratt Improvement in Blood Pressure With Inhibition of the Epithelial Sodium Channel in Blacks With Hypertension Hypertension, September 1, 2005; 46(3): 481 - 487. [Abstract] [Full Text] [PDF]

				R. Sepehrdad, P. N. Chander, G. Singh, and C. T. Stier Jr Sodium transport antagonism reduces thrombotic microangiopathy in stroke-prone spontaneously hypertensive rats Am J Physiol Renal Physiol, June 1, 2004; 286(6): F1185 - F1192. [Abstract] [Full Text] [PDF]